Literature DB >> 7524235

Treatment of benign prostatic hyperplasia by transurethral ultrasound-guided laser-induced prostatectomy (TULIP): effects on urodynamic parameters and symptoms.

J L Bosch1, J Groen, F H Schröder.   

Abstract

OBJECTIVES: This prospective study was undertaken to evaluate the effects of transurethral ultrasound-guided laser-induced prostatectomy (TULIP) on urodynamic, symptomatic, and prostate volume parameters as well as serum prostate-specific antigen.
METHODS: The TULIP procedure was performed in 33 patients with benign prostatic hyperplasia with a mean age of 66 years. Patients were evaluated by pressure-flow studies, prostate volume measurement by transrectal ultrasound, and the American Urological Association (AUA) symptom score.
RESULTS: At 3-month follow-up, laser prostatectomy has resulted in an increased maximum flow rate from 6.6 +/- 0.5 to 11.2 +/- 0.6 mL/s and in an objectively proven relief of the urodynamic obstruction, as is evident by a decrease of the average value of the urethral resistance parameter URA and the detrusor pressure at maximum flow rate from 38.3 +/- 2.7 to 21.3 +/- 1.3 cm water and from 62.7 +/- 4 to 38.9 +/- 2.1 cm water, respectively. Symptomatic improvement is evident from a decrease in the AUA symptom score from 20.4 at baseline to 8.8 at 6-month follow-up. Although the total symptom score did not change significantly between 6 months and 1 year follow-up, the score of the symptom "weak stream" was significantly higher again at 12 months follow-up.
CONCLUSIONS: The TULIP procedure is a urodynamically and symptomatically effective treatment. Conclusions about the durability of this treatment modality should be made with reservations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524235     DOI: 10.1016/s0090-4295(94)80048-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  2 in total

1.  The American Urological Association Symptom Index: early postoperative evaluation of irritative and obstructive symptoms due to benign prostatic hyperplasia.

Authors:  O Ichiyanagi; M Ishigooka; T Hashimoto; S Hayani; Y Suzuki; T Nakada
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

Review 2.  Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations.

Authors:  H J Stoevelaar; J McDonnell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.